ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Landscape Profiling Analysis of DPP4 in Malignancies: Therapeutic Implication for Tumor Patients With Coronavirus Disease 2019

Shu, Lingling*; Liu, Yang; Li, Jinyuan; Wu, Xiaoping; Li, Yang; Huang, Hanying南方医科大学; 中山大学
Frontiers in Oncology2021-2-4DOI: 10.3389/fonc.2021.624899
12被引3阅读
引用收藏
分享

摘要

Severe coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is characterized by pneumonia, lymphopenia, and cytokine storms. Patients with underlying conditions, and especially cancer patients with impaired immunity, are particularly vulnerable to SARS-CoV-2 infection and complications. Although angiotensin converting enzyme II (ACE2) has been identified as a cellular binding receptor for SARS-CoV-2, immunopathological changes in severe cancer patients support the investigation of additional potential receptors such as dipeptidyl peptidase 4 (DPP4), a key immunoregulator. However, a comprehensive profiling analysis of DPP4 in malignancies remains obscure. In this study, using different datasets, we demonstrated the expression of DPP4 in healthy tissues and pan-cancers, showing the risk of different cancer types towards SARS-CoV-2 infection according to DPP4 expression levels. DPP4 expression was positively correlated with infiltrating levels of various immune cells and showed strong correlations with diverse immune marker sets in pan-cancer patients analyzed by Tumor Immune Estimation Resource (TIMER). These findings suggest that increased DPP4 expression in specific cancer patients might account for the high susceptibility to SARS-CoV-2 infection and the induction of cytokine storms. Due to the critical role of DPP4 in immunometabolism, our results indicate that pharmacological inhibition of DPP4 might provide beneficial therapeutic effects for SARS-CoV-2 treatment together with other strategies in specific tumor patients.

学科与关键词

关键词
DPP4malignanciesimmunitySARS-CoV-2bioinformatics
相关
加载中…
  • High expression of ACE2 and TMPRSS2 and clinical characteristics of COVID-19 in colorectal cancer patients
    Liu, Chao; Wang, Kai; Zhang, Min; Hu, Xiaoyu; Hu, Tian; Liu, Yumei; Hu, Qinyong*; Wu, Shikai*; Yue, Jinbo*npj Precision Oncology, 2021, 5(1): 1.被引 29
  • Multi-omics of the expression and clinical outcomes of TMPRSS2 in human various cancers: A potential therapeutic target for COVID-19
    Liu, Li; Qin, Ju-Fang; Zuo, Man-Zhen; Zhou, Quan*Journal of Cellular and Molecular Medicine, 2022, 26(3): 709-724.被引 2
  • Evaluation and characterization of HSPA5 (GRP78) expression profiles in normal individuals and cancer patients with COVID-19
    Fu, Jiewen; Wei, Chunli; He, Jiayue; Zhang, Lianmei; Zhou, Ju; Balaji, Kyathegowdanadoddi Srinivasa; Shen, Shiyi; Peng, Jiangzhou*; Sharma, Amrish*; Fu, JunjiangInternational Journal of Biological Sciences, 2021, 17(3): 897-910.被引 27
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2021-02-04
卷期
第 11 卷
页码
624899
DOI
10.3389/fonc.2021.624899
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81700749]; Sun Yat-sen University Hundred Talents Program [PT19200101]

作者

  • S

    Shu, Lingling (通讯) (第一作者)

    sun yat sen univ

  • L

    Liu, Yang

查看全部 6 位作者收起作者
  • L

    Li, Jinyuan

    sun yat sen univ

  • W

    Wu, Xiaoping

    univ hong kong

  • L

    Li, Yang

  • H

    Huang, Hanying

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417